Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annu
02 December 2009 - 11:00PM
PR Newswire (US)
BETHESDA, Md., Dec. 2 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI), a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation
and autoimmune diseases, today announced that it will host a
webcast and conference call on, Tuesday, December 8, 2009, at 12:00
pm Eastern Time (6:00 pm Central European Time) to discuss the
blinatumomab data that was presented at the American Society of
Hematology (ASH) meeting. To access the webcast please log on to
http://www.micromet-inc.com/. It is recommended that you listen via
the webcast stream. Alternatively, participants can listen via
telephone by calling 877-552-3054 (U.S.) or 706-758-0358
(international), passcode/conference ID 43967254. An audio only
replay of the call will be available from 2:00 pm Eastern Time on
December 8, 2009 (8:00 pm Central European Time) through December
15, 2009. The replay number is 800-642-1687 (U.S.) or 706-645-9291
(international), passcode/conference ID 43967254. About BiTE
Antibodies BiTEĀ® antibodies are designed to direct the body's
cytotoxic, or cell-destroying, T cells against tumor cells, and
represent a new therapeutic approach to cancer therapy. Typically,
antibodies cannot engage T cells because T cells lack the
appropriate receptors for binding antibodies. BiTE antibodies have
been shown to bind T cells to tumor cells, ultimately inducing a
self-destruction process in the tumor cells referred to as
apoptosis, or programmed cell death. In the presence of BiTE
antibodies, T cells have been demonstrated to serially eliminate
tumor cells, which explains the activity of BiTE antibodies at very
low concentrations. Through the killing process, T cells start to
proliferate, which leads to an increased number of T cells at the
site of attack. About Micromet, Inc. Micromet, Inc. is a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases.
Its product development pipeline includes novel antibodies
generated with its proprietary BiTEĀ® antibody platform, as well as
conventional monoclonal antibodies. Two of Micromet's BiTE
antibodies and three of its conventional antibodies are currently
in clinical trials. Micromet's preclinical product pipeline
includes several novel BiTE antibodies generated with its
proprietary BiTE antibody platform technology. Micromet's
collaboration partners include sanofi-aventis, Bayer Schering
Pharma, Merck Serono, MedImmune and Nycomed. Forward-Looking
Statements This release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. These forward-looking statements include statements
regarding the development and commercialization of blinatumomab,
including the conduct and timing of future clinical trials
involving this product candidate. You are urged to consider
statements that include the words "ongoing," "may," "will,"
"believes," "potential," "expects," "plans," "anticipates,"
"intends," or the negative of those words or other similar words to
be uncertain and forward-looking. Factors that may cause actual
results to differ materially from any future results expressed or
implied by any forward-looking statements include the risk that
blinatumomab does not demonstrate safety and/or efficacy in future
clinical trials, the risk that we will not obtain approval to
market blinatumomab and the risks associated with reliance on
outside financing to meet capital requirements. These factors and
others are more fully discussed in Micromet's Quarterly Report on
Form 10-Q for the fiscal quarter ended September 30, 2009, filed
with the SEC on November 6, 2009, as well as other filings by the
company with the SEC. DATASOURCE: Micromet, Inc. CONTACT: US Media:
Chris Stamm, +1-781-684-0770, ; US Investors: Susan Noonan,
+1-212-966-3650, ; European Media: Ludger Wess, +49 (40) 8816 5964,
; European Investors: Ines-Regina Buth, +49 (30) 2363 2768, Web
Site: http://www.micromet-inc.com/
Copyright